Endpoints
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) determined 2 µg/mL of meropenem as a susceptible breakpoint of meropenem for the Gram-negative organisms (MIC). The primary pharmacodynamic endpoint of this study was the concentrations above the breakpoints for ≥50% of the dosing interval (ft>MIC ≥ 50%), and the secondary endpoint was ft>MIC= 100%.